Clinical trials: Antitumor Drug
Colorectal Cancer, Gastro Esophageal Junctional Cancer
IKS04 Regimen in Advanced Solid Tumors That Express CA242
This study will evaluate the safety, tolerability, anti-tumor activity, immunogenicity, pharmacokinetics and pharmacodynamics of the IKS04 Regimen and identify a recommended phase 2 dose (RP2D) or recommended dose for further…
- Conditions
- Colorectal Cancer, Gastro Esophageal Junctional Cancer, Gastric Cancer (GC), GEJ Adenocarcinoma
- Trial name
- NCT07738939
- Testing
- IKS04 antibody drug conjugate ADC + Isumab04 monoclonal antibody
- Where
- 4 sites in United States
- Volunteers
- 120 people
- Sponsor
- Iksuda Therapeutics Ltd.
Neoplasms
Study of a Combination of GSK1795091 and Immunotherapies in Subjects With Advanced Solid Tumors
GSK1795091 is being developed for administration in combination with other immune system modulators for the treatment of cancers. The study will be conducted in two parts.
- Trial name
- NCT03447314
- Testing
- GSK1795091, GSK3174998, GSK3359609
- Where
- 8 sites in United States, Canada and 2 more
- Volunteers
- 54 people
- Sponsor
- GlaxoSmithKline
Advanced Solid Tumors
SNV4818 in Participants With Advanced Solid Tumors
This study is testing a new medicine, SNV4818, for people with advanced cancers. The researchers want to find out if SNV4818 is safe, well-tolerated, and effective in treating solid tumors.
- Trial name
- NCT06736704
- Testing
- SNV4818, Fulvestrant, Palbociclib
- Where
- 12 sites in United States, Australia and 1 more
- Volunteers
- 320 people
- Sponsor
- Pikavation Therapeutics, Inc.
Breast Cancer, Bone Marrow Suppression
A Randomized, Self-controlled Post-marketing Clinical Study on the Comparison of Shengbai Oral Liquid and Leucogen Tablets in the Treatment of Moderate Neutropenia Caused by Anti-tumor Drugs in Breast Cancer Patients
The subjects were randomly assigned to Group A or Group B in a 1:1 ratio, stratified by early/late stage. Group A: In the first cycle, they took Shengbai Oral Liquid (40 ml, three times a day), and in the second cycle, they took…
- Trial name
- NCT07578064
- Testing
- Group A, Group B
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Hongxia Wang
Non Small Cell Lung Cancer, Pancreatic Ductal Adenocarcinoma
A First-in-Human Study of CAN04 in Patients With Solid Malignant Tumors
This study will evaluate the safety, tolerability, and preliminary antitumor activity of CAN04 both as a monotherapy and in combination with standard of care treatment in subjects with solid cancer tumors.
- Conditions
- Non Small Cell Lung Cancer, Pancreatic Ductal Adenocarcinoma, Triple Negative Breast Cancer, Colorectal Cancer
- Trial name
- CANFOUR (NCT03267316)
- Testing
- CAN04, Cisplatin, Gemcitabine
- Where
- 25 sites in Austria, Belgium and 9 more
- Volunteers
- 167 people
- Sponsor
- Cantargia AB
Neoplasms
Rapid Analysis and Response Evaluation of Combination Anti-Neoplastic Agents in Rare Tumors (RARE CANCER) Trial: RARE 1 Nilotinib and Paclitaxel
Background: People with rare cancers often have limited treatment options. The biology of rare cancers is not well understood. Researchers want to find better treatments for these cancers.
- Trial name
- NCT04449549
- Testing
- Nilotinib and Paclitaxel
- Where
- United States
- Volunteers
- 82 people
- Sponsor
- National Cancer Institute (NCI)
Acute Myeloid Leukemia, Chronic Lymphocytic Leukemia
Safety, Tolerability Study of SG2000 in the Treatment of Advanced Chronic Lymphocytic Leukemia and Acute Myeloid Leukemia
The purpose of this study is to determine if the experimental drug, SG2000 is safe and tolerable in the treatment of participants with advanced chronic lymphocytic leukemia and acute myeloid leukemia whose standard treatment did…
- Trial name
- NCT02034227
- Testing
- SG2000
- Where
- 2 sites in United States
- Volunteers
- 6 people
- Sponsor
- Spirogen
Clear-cell Metastatic Renal Cell Carcinoma, Kidney Neoplasms
IMaging PAtients for Cancer Drug selecTion - Renal Cell Carcinoma (IMPACT-RCC)
Rationale. In part of the patients with good and intermediate risk metastatic renal cell carcinoma (mRCC) the disease course is indolent and immediate start of systemic therapy is not necessary.
- Trial name
- IMPACT-RCC (NCT02228954)
- Testing
- Molecular imaging
- Where
- 3 sites in Netherlands
- Volunteers
- 40 people
- Sponsor
- Radboud University Medical Center
Carcinoma, Pancreatic Ductal, Colorectal Neoplasms
A Study to Learn About the Study Medicine PF-07985045 When Given Alone or With Other Anti-cancer Therapies in People With Advanced Solid Tumors That Have a Change in a Gene.
The purpose of this study is to learn about the safety and effects of the study medicine when given alone or together with other anti-cancer therapies. Anti-cancer therapy is a type of treatment to stop the growth of cancer.
- Conditions
- Carcinoma, Pancreatic Ductal, Colorectal Neoplasms, Carcinoma, Non-Small-Cell Lung
- Trial name
- NCT06704724
- Testing
- PF-07985045, Gemcitabine, Nab-paclitaxel
- Where
- 13 sites in United States, Puerto Rico
- Volunteers
- 30 people
- Sponsor
- Pfizer
Neuroendocrine (NE) Tumors, Oral Anti-Tumor Drugs
Evaluation of Tolerance and Quality of Life in Patients With Neuroendocrine Tumors Treated With Oral Anti-Tumor Drugs Within a Therapeutic Education Program
In recent years, the arrival of targeted oral therapies has greatly changed cancer treatment. These therapies help patients stay independent by reducing the number of hospital visits, since the treatment is given at home.
- Conditions
- Neuroendocrine (NE) Tumors, Oral Anti-Tumor Drugs, Therapeutic Education Program
- Trial name
- ETP-NET (NCT07258810)
- Testing
- Questionnaires
- Where
- France
- Volunteers
- 100 people
- Sponsor
- Hospices Civils de Lyon
Cancer
Impact of a Coordinated Regional Organization to Secure Patient's Care Treated by Oral Antineoplastic Agents
The purpose is to estimate evolution of patients treated by oral neoplastic agents, in term of early or unforeseen recourse to the hospital for adverse events.
- Trial name
- CHIMORAL (NCT01947296)
- Where
- France
- Volunteers
- 284 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Cardiovascular Diseases, Cardiac Diseases
Pharmacovigilance Assessment of Reporting of Cardiovascular Adverse Events With Antineoplastic Agents (PARCA)
The aim of this observational study is to explore and analyze reports of cardiac or vascular adverse events linked to the administration of antineoplastic agents among patients diagnosed with tumors represented by advanced…
- Conditions
- Cardiovascular Diseases, Cardiac Diseases, Vascular Diseases, Cancer
- Trial name
- PARCA (NCT06409481)
- Testing
- Antineoplastic Agents
- Volunteers
- 800,000 people
- Sponsor
- The First Affiliated Hospital of Xinxiang Medical College
Sarcoma, Kaposi, HIV Infections
A Study of Tecogalan Sodium
To evaluate the safety of different doses and dosing regimens of tecogalan sodium (DS-4152) and to establish the MTD at each of the different dosing schedules.
- Trial name
- NCT00002342
- Testing
- Tecogalan sodium
- Where
- United States
- Sponsor
- Daiichi Pharmaceuticals
Non Hodgkin Lymphoma
Phase1/2 Study of IPH6501 in Patients With Relapsed /Refractory B-Cell Non-Hodgkin Lymphoma
This is an international, first-in-human, multicenter, open-label Phase 1/2 study to evaluate the safety profile, tolerability of IPH6501, and determine the recommended phase 2 dose (RP2D) for patients with B-Cell non-Hodgkin…
- Trial name
- NCT06088654
- Testing
- IPH6501
- Where
- 14 sites in United States, Australia and 1 more
- Volunteers
- 23 people
- Sponsor
- Innate Pharma
Neoplasms
Study of the Safety and Effectiveness of GSK6097608 in Participants With Advanced Solid Tumors
This first-time-in-human (FTIH) study will evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and preliminary clinical activity of escalating doses of GSK6097608 given as monotherapy and in…
- Trial name
- NCT04446351
- Testing
- GSK6097608, Dostarlimab, Cobolimab
- Where
- 11 sites in United States, Canada and 2 more
- Volunteers
- 107 people
- Sponsor
- GlaxoSmithKline
Chemotherapeutic Agent Toxicity, Mucositis
Selenomethionine in Reducing Mucositis in Patients With Locally Advanced Head and Neck Cancer Who Are Receiving Cisplatin and Radiation Therapy
This randomized phase II trial is studying how well selenomethionine (SLM) works in reducing mucositis in patients with locally advanced head and neck cancer who are receiving cisplatin and radiation therapy.
- Conditions
- Chemotherapeutic Agent Toxicity, Mucositis, Radiation Toxicity, Stage III Squamous Cell Carcinoma of the Hypopharynx
- Trial name
- NCT01682031
- Testing
- selenomethionine, cisplatin, radiation therapy
- Where
- 2 sites in United States, New Zealand
- Volunteers
- 18 people
- Sponsor
- Roswell Park Cancer Institute
Metastatic Colorectal Adenocarcinoma, Refractory Colorectal Adenocarcinoma
Testing the Effectiveness of the Anti-cancer Drug Pidnarulex (CX-5461), in Combination With Another Anti-cancer Drug Cemiplimab (REGN2810), in Treating Refractory Microsatellite Stable Colorectal Cancer
This phase I/II trial studies the side effects and best dose of pidnarulex when given together with cemiplimab and to see how well it works in treating patients with microsatellite stable (MSS) colorectal cancer (CRC) that does…
- Conditions
- Metastatic Colorectal Adenocarcinoma, Refractory Colorectal Adenocarcinoma, Stage III Colorectal Cancer AJCC v8, Stage IV Colorectal Cancer AJCC v8
- Trial name
- NCT07147231
- Testing
- Biopsy Procedure, Biospecimen Collection, Cemiplimab
- Where
- 7 sites in United States
- Volunteers
- 86 people
- Sponsor
- National Cancer Institute (NCI)
Breast Cancer, Chemotherapeutic Agent Toxicity
S0715: Acetyl-L-Carnitine in Preventing Neuropathy in Women With Stage I, II, or IIIA Breast Cancer Undergoing Chemo
RATIONALE: Acetyl-L-carnitine may prevent or lessen neuropathy caused by chemotherapy. It is not yet known whether acetyl-L-carnitine is more effective than a placebo in preventing neuropathy caused by chemotherapy.
- Conditions
- Breast Cancer, Chemotherapeutic Agent Toxicity, Fatigue, Neuropathy
- Trial name
- NCT00775645
- Testing
- acetyl-L-carnitine hydrochloride
- Where
- 295 sites in United States
- Volunteers
- 437 people
- Sponsor
- SWOG Cancer Research Network
Prostate Cancer, Prostate Adenocarcinoma
Effects of Direct Artery Injection on Prostate Cancer Drug Delivery and Tumor Uptake: Imaging-Based Prediction of Treatment Effectiveness
The goal of this clinical trial is to learn whether intra-arterial (IA) administration of 68Ga-PSMA improves tumor uptake and distribution compared with standard intravenous (IV) administration in patients with localized…
- Trial name
- IAPSMA (NCT07656337)
- Testing
- Intraarterial injection of 68Ga-PSMA
- Where
- Lithuania
- Volunteers
- 10 people
- Sponsor
- Lithuanian University of Health Sciences
Chemotherapy-induced Nausea and Vomiting
Prevalence of Anticipatory Nausea and Vomiting in Cancer Patients Exposed to Highly Emetogenic Chemotherapy
Chemotherapy induced nausea and vomiting are common adverse events related to oncologic treatments. It can have deleterious effect on patients' quality of life and could lead to dose reductions and/or discontinuation of…
- Trial name
- NCT04785495
- Testing
- Quality-of-life assessment
- Where
- Brazil
- Volunteers
- 50 people
- Sponsor
- Instituto Brasileiro de Controle do Cancer